Comparative and Functional Genomics最新文献

Even though there is strong evidence that exercise improves breast cancer patients′ quality of life, treatment tolerance, and survival, disparate research initiatives and uneven clinical acceptance underscore the need for a thorough synthesis of trends, partnerships, and gaps. This bibliometric analysis systematically maps the research landscape of exercise and cardiovascular disease (CVD) from 2020 to 2024, aiming to identify trends, influential works, and knowledge gaps in this critical field. Utilizing data from the Web of Science (WoS) and VOSviewer, the study analyzed 314 articles through cocitation, coword, and co-occurrence analyses. Key findings reveal exponential growth in citations, driven by seminal guidelines (e.g., ESC 2021 and WHO 2020) and studies on sedentary behavior and pandemic-related activity changes. The intellectual structure is anchored by three themes: evidence-based guidelines, risk quantification (e.g., dose–response relationships), and behavioral interventions. Dominant journals include the British Journal of Sports Medicine and JAMA, while influential authors like Dominique Hansen and Emmanuel Stamatakis shape the field. Geographic disparities highlight Western-centric research dominance, though emerging contributions from Asia and Europe are noted. The study identifies gaps in mechanistic research, personalized exercise prescriptions, and equitable translation of evidence into practice. Practical implications call for standardized clinical protocols, dual public health messaging (activity promotion and sedentary reduction), and digital health integration. This analysis provides a roadmap for future research, emphasizing transdisciplinary collaboration to optimize CVD prevention through physical activity.

Acute respiratory distress syndrome (ARDS) is a critical condition characterized by diffuse alveolar damage and intense inflammatory responses. During the COVID-19 pandemic, its incidence and mortality have remained persistently high. Conventional approaches have struggled to uncover the complex cellular heterogeneity and dynamic inflammatory networks underlying ARDS. The advent of single-cell sequencing technologies has revolutionized our ability to dissect the molecular mechanisms of ARDS. This review systematically summarizes recent advances in the application of single-cell sequencing in studying pulmonary inflammation in ARDS, with a focus on its strengths in elucidating immune cell heterogeneity, reconstructing intercellular communication networks, and identifying potential therapeutic targets. Furthermore, we discuss current technical limitations and translational challenges, aiming to provide a theoretical foundation and future direction for translating mechanistic insights into precision medicine for ARDS.

Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis-related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high- and low-risk groups with significantly different overall survival outcomes. Functional enrichment and immune-related analyses revealed that the high-risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune-related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high-risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.